After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Banking on its Rayaldee treatment, this once-quiet pharmaceutical company has stepped up its investor profile with its first analyst day and a recent move to Nasdaq.
Trade-Ideas LLC identified Opko Health (OPK) as a weak on high relative volume candidate
Opko (OPK) stock is up this morning after the FDA approved its drug Rayaldee.
Markets are projecting a positive open as Brexit-worries have abated.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.